1 citations
,
August 2005 in “Springer eBooks” Alopecia areata is an autoimmune disease with genetic links, treatable with certain medications, and can affect mental health.
The document concludes that diagnosing female hair loss requires careful examination, with treatments varying by condition and psychological support often necessary.
July 2016 in “Experimental Dermatology” New treatments for hair growth and psoriasis may be possible, and gene differences could affect baldness and the severity of skin conditions.
March 2026 in “Frontiers in Medicine” Different types of alopecia cause hair loss due to immune system issues, with some allowing regrowth and others causing permanent loss.
March 2026 in “JID Innovations” Aire mutation reduces alopecia areata, while Notch4 mutation prevents it in mice.
February 2026 in “Journal of Allergy and Clinical Immunology” Alopecia areata involves immune system issues and specific cell types that disrupt hair growth, leading to hair loss.
January 2026 in “Journal of Investigative Dermatology” Special cells can help regrow hair in alopecia areata.
December 2025 in “International Journal of Molecular Sciences” Exosome-based therapies show promise for treating alopecia areata but need more research.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
October 2025 in “International Journal of Molecular Sciences” Early intervention in patch-type alopecia may prevent progression to more severe forms by targeting immune pathways and preserving keratin.
September 2025 in “Diseases” Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.
July 2025 in “Pharmaceuticals” Phenobarbital-loaded chitosan nanoparticles are promising for preventing hair loss from chemotherapy.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
May 2025 in “Journal of the Egyptian Womenʼs Dermatologic Society” Vitamin D3 is a safe and effective alternative to steroids for treating alopecia areata, with fewer side effects.
January 2025 in “The Journal of Dermatology” Certain patient traits can predict better hair regrowth with baricitinib in severe alopecia areata.
January 2025 in “Lasers in Medical Science” CO2 fractional laser treatment helped regrow hair in a 13-year-old with alopecia areata.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
December 2024 in “Journal of Clinical Medicine” Minoxidil shows promise for alopecia areata, but more research is needed before it can be recommended as a primary treatment.
October 2024 in “JEADV Clinical Practice” UK dermatologists commonly use corticosteroids and minoxidil to treat hair loss conditions.
September 2024 in “Journal of Cosmetic Dermatology” Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.
August 2024 in “International Journal of Molecular Sciences” Mesenchymal Stem Cell therapy shows promise for treating hair loss in Alopecia Areata.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
May 2024 in “Frontiers in Immunology” Type-2 immunity may influence skin diseases and could be targeted for treatment.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
April 2024 in “International journal of molecular sciences” Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
Baricitinib may effectively treat oral lichen planus.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
January 2024 in “Case Reports in Endocrinology” Cortisone tapering may help improve severe myasthenia gravis and alopecia areata after thymectomy.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.